Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Race Oncology Limited (RAC.AX)
AUD2.23
+0.07 (+3.24%)
AU ASX Healthcare Biotechnology
Address
Gateway, 1 Macquarie Place 2000
Sydney, NSW, AU
Sydney, NSW, AU
CEO
Daniel Tillett
Website
raceoncology.com
IPO
2016-07-13
ISIN AU000000RAC3
Also trades on
Australian Securities Exchange · RAC.AX (AUD)
Other OTC · RAONF (USD)
Description
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. The company maintains an active preclinical research program with the University of Newcastle, focusing on Zantrene, and has also forged a strategic alliance with the University of Wollongong to assess various formulations of the drug. Established in 2011, Race Oncology Limited adopted its current name in July 2016, having previously operated as Coronado Resources Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD2.23
+0.07 (+3.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
184.6K
Beta
0.83
Float Shares
127.08M
Free Float %
66.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.98% | +3.20% | -1.15% | +4.45% | -9.47% | -5.49% | +113.22% | +74.32% | -24.78% | +873.58% | +873.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.23
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
236.97
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+51.0% ★ Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+66.9% ★ Q4'25: +32.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-3.7%
-
EBIT margin Biotechnology: +0.0%-78.0%
-
ROIC Biotechnology: -16.1%-201.0% Q4'25: -516.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+4.8% Q4'25: +7.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
170.3K
est: 500.0K (-65.9%)
|
—
est: 500.0K (-100.0%)
|
159.4K
est: 200.0K (-20.3%)
|
387.4K
est: 387.0K (+0.1%)
|
707.8K
est: 34.90M (-98.0%)
|
3.13M
est: 14.40M (-78.2%)
|
6.04M
est: 4.80M (+25.9%)
|
2.80M
2.80M – 2.80M
-41.7% YoY
|
1.10M
1.10M – 1.10M
-60.7% YoY
|
5.20M
5.20M – 5.20M
+372.7% YoY
|
| EBITDA |
-6.23M
est: -473.4K (-1,215.2%)
|
-3.61M
est: -473.4K (-662.0%)
|
-3.72M
est: -189.3K (-1,866.7%)
|
-6.45M
est: -366.4K (-1,659.6%)
|
-11.63M
est: -33.04M (+64.8%)
|
-12.78M
est: -13.63M (+6.3%)
|
-4.43M
est: -4.54M (+2.4%)
|
-2.65M
-2.65M – -2.65M
+41.7% YoY
|
-1.04M
-1.04M – -1.04M
+60.7% YoY
|
-4.92M
-4.92M – -4.92M
-372.7% YoY
|
| EBIT |
-6.48M
est: -478.0K (-1,255.0%)
|
-3.89M
est: -478.0K (-713.3%)
|
-4.01M
est: -191.2K (-1,994.6%)
|
-6.73M
est: -370.0K (-1,718.4%)
|
-11.91M
est: -33.37M (+64.3%)
|
-13.06M
est: -13.77M (+5.2%)
|
-4.72M
est: -4.59M (-2.7%)
|
-2.68M
-2.68M – -2.68M
+41.7% YoY
|
-1.05M
-1.05M – -1.05M
+60.7% YoY
|
-4.97M
-4.97M – -4.97M
-372.7% YoY
|
| Net Income |
-6.31M
est: -931.04M (+99.3%)
|
-3.66M
est: -1.16B (+99.7%)
|
-3.85M
|
-6.34M
est: -5.50M (-15.3%)
|
-11.20M
est: 15.86M (-170.6%)
|
-9.92M
est: -12.59M (+21.2%)
|
-4.79M
est: -14.48M (+66.9%)
|
-6.90M
-6.90M – -6.90M
+52.4% YoY
|
-17.76M
-17.76M – -17.76M
-157.5% YoY
|
-13.45M
-13.45M – -13.45M
+24.3% YoY
|
| SGA |
3.87M
est: 2.17M (+78.0%)
|
2.30M
est: 2.17M (+6.0%)
|
1.68M
est: 868.8K (+93.5%)
|
4.00M
est: 1.68M (+137.7%)
|
5.37M
est: 151.61M (-96.5%)
|
5.11M
est: 62.56M (-91.8%)
|
3.28M
est: 20.85M (-84.3%)
|
12.16M
12.16M – 12.16M
-41.7% YoY
|
4.78M
4.78M – 4.78M
-60.7% YoY
|
22.59M
22.59M – 22.59M
+372.7% YoY
|
| EPS |
-0.09
est: -5.40 (+98.3%)
|
-0.05
est: -6.70 (+99.3%)
|
-0.04
|
-0.05
est: -0.03 (-51.7%)
|
-0.07
est: 0.09 (-179.1%)
|
-0.06
est: -0.07 (+15.5%)
|
-0.03
est: -0.08 (+66.9%)
|
-0.04
-0.04 – -0.04
+52.4% YoY
|
-0.10
-0.10 – -0.10
-157.5% YoY
|
-0.08
-0.08 – -0.08
+24.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
EBIT / Employee
-943.0K
Shares Outstanding
192.31M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jose L. Iglesias | Chief Medical Officer | 471.2K | — |
| Daniel Tillett | Chief Executive Officer, Managing Director & Director | 463.7K | — |
| Peter Smith | Executive Chairman | 459.7K | — |
| Brendan Brown | Chief Financial Officer | — | male |
| Peter Gordon Webse FCIS FCPA FGIA | Company Secretary | — | male |
| Sophia Moscovis | Vice President of Operations & Strategy | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RAC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
